Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabeti... ( Insulin is a hormone that regulate...)

HOME >> MEDICINE >> TECHNOLOGY

Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients

Date:1/20/2010

Insulin is a hormone that regulates blood glucose levels. Diabetes can seriously impair overall quality of life and may lead to multiple complications including heart disease, stroke, and kidney failure. According to the International Diabetes Federation, more than 245 million people have diabetes, with type 2 diabetes being the most prevalent.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to the characterization of the safety and efficacy profile of LX4211 observed in the Phase 2 clinical trial as positive or favorable, the characterization of the results of the Phase 2 clinical trial of LX4211 as demonstrating the potential for a therapeutic benefit for patients with type 2 diabetes, and the potential therapeutic and commercial potential of LX4211 generally. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, di
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease

Post Your Comments:

(Date:5/23/2013)... 24 de mayo de 2013 Volcano Corporation ... y fabricante de herramientas de precisión para terapia ... de la enfermedad vascular periférica y coronaria, anunció ... Ad enosine V asodilator I ndependent ... la sesión de ensayo clínico hot line late ...

(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering. In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering. A portion of the ...

(Date:5/23/2013)... , May 23, 2013 TeamHealth Medical ... nurse triage and nurse advice lines, announces its ... comprising physician, nursing and administrative leaders, provides clinical ... quality and cost-effective services for hospital clients, physician ... national healthcare system evolves, it,s imperative to continuously ...

Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2 Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3 Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4 Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5 Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4 TeamHealth Medical Call Center Forms Clinical Advisory Committee 2

[0] Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 [0] Nephros Announces Completion of Rights Offering [0] TeamHealth Medical Call Center Forms Clinical Advisory Committee

... On Thursday, the U.S. Food and Drug Administration approved ... located in the pancreas (PNET) that cannot be removed ... of the body (metastatic). (Logo: ... pancreas are slow-growing and rare. It is estimated that ...

... Calif., May 6, 2011 CryoLife, Inc. (NYSE: ... cardiovascular tissue processing company, today announced the final results ... wholly owned subsidiary CL Falcon, Inc., for 49.9 percent ... CGCP). The tender offer expired at 12:00 midnight, Eastern ...

Cached Medicine Technology:FDA Approves New Treatment for Rare Type of Pancreatic Cancer 2 CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2 CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3 CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4 CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5 CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6

FDA Approves New Treatment for Rare Type of Pancreatic Cancer CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation

(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...

(Date:5/24/2013)... Seattle, WA (PRWEB) May 24, 2013 ... consider when picking out a home security monitoring ... comparisons help make 6Webs.com the useful resource consumers prefer ... recently completed performing their evaluations of the leading wireless ... home security companies are rated on a number of ...

(Date:5/24/2013)... 2013 The Dictation Source recently added ... clients. As a result of its National marketing efforts, ... 20 states around the nation. , Since 1991, The ... to the healthcare industry . Dictation Source is owned ... years of clinical work experience to provide the solutions ...

(Date:5/24/2013)... The number of U.S. patients admitted to hospitals, ... emergency room has increased by nearly 50 percent, ... by researchers at the George Washington University School ... D.C., found that patients wait five hours in ... to the ICU. The researchers said improved coordination ...

(Date:5/24/2013)... Australia (PRWEB) May 24, 2013 ... off their favorite sunglasses all while learning how ... with replacement lenses. Contestants only need to ... their sunglasses and "like" The Sunglass Fix on ... Sunglass fix is the largest lens replacement ...

Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2 Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3 Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4 Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2 Health News:The Dictation Source Signs Two National Hospital Chains 2 Health News:The Dictation Source Signs Two National Hospital Chains 3 Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2 Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2

[0] Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York [0] 2013 Best Wireless Security System Providers Reported by 6Webs.com [0] The Dictation Source Signs Two National Hospital Chains [0] Sharp Rise in ICU Admissions From U.S. Emergency Rooms [0] Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win

... Now,s the Time to Write or Call Your Representatives, ... Although President Obama has called for affordable, accessible, high-quality ... legislation will bridge the long term care gap," says ... of our 300 million plus, have long term care ...

... (Nasdaq: PRXL ) announced today it will be ... in New York. Josef von Rickenbach, Chairman & Chief ... at 3:10 p.m. EDT on Tuesday, June 9, 2009. ... the "Investor Relations - Upcoming Events" section of ...

... Solutions, Inc. (MHS), a leader in the field of physical inventory ... Epstein Becker & Green, P.C., has joined the MHS Board of ... ... Management Health Solutions, Inc. (MHS) , a leader in the ...

... Can Test So You Can Rest , ... New York (Vocus) May 28, 2009 -- ... to it, don,t even know. Snoring is more than an annoyance. ... problems. The member dentists of Snoring Isn,t Sexy® have united to ...

... Of Every Federal And State Dollar Spent, 96 Cents Goes ... 2 Cents Goes to Prevention and TreatmentWASHINGTON, May 28 ... local governments at least $467.7 billion in 2005, according to ... Federal, State and Local Budgets, a new 287-page report ...

... you?WASHINGTON, May 27 Ariana-Leilani, "The Little Ambassador" is ... life has met with Former President Bush, Nobel Peace ... of Swaziland and the current Ambassadors to the USA ... blood disorder which could be fatal if it continues ...

Cached Medicine News:Health News:Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform 2 Health News:Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform 3 Health News:PAREXEL International to Present at Goldman Sachs Annual Global Healthcare Conference and the Jefferies Annual Healthcare Conference 2 Health News:Steven B. Epstein Joins Board of Management Health Solutions, Inc. 2 Health News:Snoring Isn't Sexy Launches Public Awareness Campaign 2 Health News:New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction 2 Health News:New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction 3 Health News:New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction 4 Health News:New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction 5 Health News:Family Prayer Candle Light Vigil for Life-Saving Rescue of 6-year-old 'Little Ambassador' 2

Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform PAREXEL International to Present at Goldman Sachs Annual Global Healthcare Conference and the Jefferies Annual Healthcare Conference Steven B. Epstein Joins Board of Management Health Solutions, Inc.Snoring Isn't Sexy Launches Public Awareness Campaign New CASA* Report Finds Federal, State and Local Governments Spend Almost Half a Trillion Dollars a Year on Substance Abuse and Addiction Family Prayer Candle Light Vigil for Life-Saving Rescue of 6-year-old 'Little Ambassador'

Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....

... The INFINITI 4F, ... of diagnostic catheters is ... These products incorporate state-of-the-art ... nylon to deliver better ...

... complete offering of cardiology catheters. Available in ... are designed with excellent torque, new wire-braid ... push-ability, and large inner lumens for excellent ... and 7 French sizes with pressure ratings ...

Medicine Products:

6F Infiniti 5F Infiniti Infinity Softtouch